Business
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., July 10, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company’s Scientific Advisory Board (SAB). Dr.
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/6f441b52582d191f1dda2c1a803ca2c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MUWakRWg9K34XW0Y3l_CWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6f441b52582d191f1dda2c1a803ca2c5","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Oybgzaywud6DGw_FpAZ11Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6f441b52582d191f1dda2c1a803ca2c5","width":1121,"height":442}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., July 10, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company’s Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince’s SAB, which is comprised of leading experts in Ataxia-Telangiectasia (A-T), biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice.","length":740,"tagName":"p"},{"type":"text","content":"Dr. Mauro Magnani, Ph.D., Chair of Quince’s Scientific Advisory Board, said, "Quince is excited to welcome leading immunologist and researcher Dr. Abolhassani as a new member of our SAB. Given his notable work in immunodeficiency disorders, as well as the rare pediatric neurodegenerative disease Ataxia-Telangiectasia, we expect to benefit from his unique insight and expertise as the SAB continues to support Quince as the company advances its potentially breakthrough ability to deliver corticosteroid treatment without toxicities with its lead asset eDSP."","length":570,"tagName":"p"},{"type":"text","content":"Dr. Hassan Abolhassani said, "It is an honor to join Quince’s SAB at this exciting time as the company prepares to report topline results in the first quarter of 2026 evaluating the company’s lead as...